The global bispecific antibody (BsAb) market has witnessed significant growth, with 17 bispecific antibody therapies already ...

Bispecific antibodies targeting multiple SARS-CoV-2 sites offer enhanced neutralization against emerging variants, advancing ...

In the latest move to cement its “immunology powerhouse” status, Sanofi is handing ove | The CD20-directed antibody, dubbed ...

The trispecific antibody market is rapidly advancing, with 50+ candidates in clinical trials and first approvals expected by 2028. These next-gen immunotherapies target three distinct antigens, ...

A Stanford-led team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is ...

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology EP: 2 . Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug ...

In September 2024, announced an exclusive worldwide license agreement with BioAtla, Inc. to develop and commercialize CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody. Context expects to ...

ImmunoPrecise announced a partnership with a biotechnology giant to develop ADCs and bispecific antibodies for the treatment ...

Continues focus on development of bispecific anti-cancer agents with differentiated mechanisms of action SEATTLE, WASHINGTON / ACCESS Newswire / March 18, 2025 / Aptevo Therapeutics (NASDAQ:APVO), a l ...

In myeloma treatment, acute CRS is a common but treatable AE associated with CAR T-cell therapy and bispecific antibodies, ...